Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
September 19 2017 - 4:01PM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon tetracycline chemistry, today
announced that the Company will host an Investor Day on Tuesday,
October 17, 2017 from 12:00 p.m. to 3:00 p.m. ET at the Lotte New
York Palace in New York City. During the Investor Day, Paratek’s
management team and experts in the field of antibiotics development
and infectious disease will discuss progress of the clinical
development program and pre-commercialization activities for
omadacycline. The meeting will feature presentations by key opinion
leaders including:
- Charles V. Pollack, Jr., M.D., Thomas Jefferson University
- George Zhanel, Ph.D., University of Manitoba
- George Sakoulas, M.D., University of California San Diego
To register for the event, please visit:
http://events.constantcontact.com/register/event?llr=mlhnstzab&oeidk=a07eeli0jt86b51bd56
Webcast Information A live webcast of the Investor
Day and replay will be available online from the Events and
Presentations section of Paratek’s website at
www.paratekpharma.com. A replay of the presentation will be posted
on the Paratek website approximately one hour after the live event
and will be available for 30 days following the presentation.
About ParatekParatek Pharmaceuticals, Inc. is
a biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon its expertise
in novel tetracycline chemistry. The Company’s lead product
candidate, omadacycline, is a new, once-daily oral and intravenous
broad-spectrum antibiotic being developed for the treatment of
serious community-acquired bacterial infections, including
community-acquired bacterial pneumonia (CABP), acute bacterial skin
and skin structure infections (ABSSSI), and urinary
tract infections. Omadacycline has been granted Qualified
Infectious Disease Product designation and Fast Track status by
the U.S. Food and Drug Administration for the target
indications of ABSSSI, CABP and cUTI. Paratek has completed Phase 3
development activities for omadacycline in CABP and ABSSSI and is
preparing to submit marketing applications in the United States and
European Union. Paratek has licensed rights for omadacycline to Zai
Lab for the greater China region, and retains all remaining global
rights. Under a research agreement with the U.S. Department of
Defense, omadacycline also is being studied against pathogenic
agents causing infectious diseases of public health and biodefense
importance, including plague and anthrax. Paratek's second Phase 3
product candidate, sarecycline, is being developed by Allergan in
the U.S. as a new once-daily oral therapy for the treatment of
acne. Allergan has completed Phase 3 development activities
for sarecycline and is preparing a new drug application for
submission to the U.S. Food and Drug Administration. Paratek
retains all ex-U.S. rights to sarecycline. Recognizing the serious
threat of bacterial infections, Paratek is dedicated to providing
solutions that enable positive outcomes and lead to better patient
stories. For more information, visit www.paratekpharma.com or
follow @ParatekPharma on Twitter.
CONTACTS:
Media Relations: |
|
Investor
Relations: |
Michael Lampe |
|
Hans Vitzthum |
(484) 575-5040 |
|
LifeSci Advisors,
LLC. |
michael@scientpr.com |
|
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Sep 2023 to Sep 2024